BPX-501

BIOLOGICAL2 trials

Sponsors

Bellicum Pharmaceuticals

Conditions

Hematologic MalignanciesHematologic NeoplasmsLeukemiaLymphomaMultiple MyelomaMyelodysplastic Syndromes

Phase 1

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

Active, not recruitingNCT02477878

Bellicum PharmaceuticalsHematologic Neoplasms, Leukemia, Lymphoma +2

Start: 2016-07-31End: 2033-01-31Updated: 2022-07-12

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

WithdrawnNCT02487459

Bellicum PharmaceuticalsHematologic Malignancies

Start: 2016-07-31End: 2017-06-30Updated: 2020-10-05